Definitely not a stupid question it is really important! There are several novel ways to deliver drugs to tumors in the brain in trials. Some use specially designed pumps, nanotechnology, and intra-arterial delivery…
1. Could you clarify your question on this please? We won't be replacing the pathologist report for the oncologist. We also don't obtain the tumor after their analysis and report. Our testing will be running in…
This is a really great point srunni thank you for bringing it up. We agree that the current approach to identifying predictive cancer biomarkers has many challenges. That's why we believe in a different approach.…
Thanks for your questions! Yes we'll be testing combinations, as this brain cancer has not responded historically to single agent therapy for decades. With combinations of existing drugs it is possible to affect…
Very cool! I'd love to follow up with you if you'd be interested, imaging is a major problem in this disease. 1. Great question, this is why we'll be focused on newly diagnosed glioblastoma patients. If they do recur…
Definitely not a stupid question it is really important! There are several novel ways to deliver drugs to tumors in the brain in trials. Some use specially designed pumps, nanotechnology, and intra-arterial delivery…
1. Could you clarify your question on this please? We won't be replacing the pathologist report for the oncologist. We also don't obtain the tumor after their analysis and report. Our testing will be running in…
This is a really great point srunni thank you for bringing it up. We agree that the current approach to identifying predictive cancer biomarkers has many challenges. That's why we believe in a different approach.…
Thanks for your questions! Yes we'll be testing combinations, as this brain cancer has not responded historically to single agent therapy for decades. With combinations of existing drugs it is possible to affect…
Very cool! I'd love to follow up with you if you'd be interested, imaging is a major problem in this disease. 1. Great question, this is why we'll be focused on newly diagnosed glioblastoma patients. If they do recur…